申请人:Hepion Pharmaceuticals, Inc.
公开号:US20220168385A1
公开(公告)日:2022-06-02
Disclosed herein include methods, compositions, and kits suitable for use in preventing/treating a thromboembolic disorder, preventing/reducing formation of thrombi, and reducing/inhibiting procoagulant platelet formation. The methods comprise administering to a subject in need thereof a composition comprising a cyclosporine analogue (for example, CRV431). The compositions and kits comprise a cyclosporine analogue.